NCT06502015 Biomarkers in Autoimmune Disease of Nervous System
| NCT ID | NCT06502015 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tongji Hospital |
| Condition | Autoimmune Diseases of the Nervous System |
| Study Type | OBSERVATIONAL |
| Enrollment | 50,000 participants |
| Start Date | 2024-07-31 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50,000 participants in total. It began in 2024-07-31 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Neurological autoimmune diseases are a group of disorders characterized by the abnormal immune response attacking the nervous system, including the brain, spinal cord and peripheral nerves. These diseases exhibit high heterogeneity, diverse clinical presentations, and are challenging to diagnose and manage due to a lack of effective treatments. In this study, the investigators will recruit eight kinds of autoimmune diseases of nervous system including Neuromyelitis Optica Spectrum Disorder (NMOSD), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), idiopathic inflammatory myopathy (IIM), and multiple sclerosis (MS), autoimmune encephalitis (AE), Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD). Through this study, the investigators aim to discover biomarkers with high sensitivity, specificity, and stability, which can support early diagnosis, disease monitoring, and personalized treatment for neurological autoimmune diseases, thereby improving the quality of life and prognosis for patients.
Eligibility Criteria
Inclusion Criteria: * Clinical diagnosis with autoinflammatory diseases of the nervous system, including: Neuromyelitis Optica Spectrum Disorder (NMOSD), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), idiopathic inflammatory myopathy(IIM), multiple sclerosis (MS), autoimmune encephalitis (AE), Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), ect al. * sex and age-matched healthy individuals Exclusion Criteria: * Known history of primary immunodeficiency (innate or acquired). * Patients with severe central nervous system, pulmonary, or other systemic infections. * Patients with secondary central nervous system demyelinating lesions, such as those caused by vasculitis, systemic lupus erythematosus, and Sjögren's syndrome. * Patients with vascular (including hemorrhagic and ischemic), hereditary metabolic, neoplastic, or toxic diseases. * Pregnant or lactating women.
Contact & Investigator
Dai-shi Tian, MD
PRINCIPAL INVESTIGATOR
Tongji Hospital
Frequently Asked Questions
Who can join the NCT06502015 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Autoimmune Diseases of the Nervous System. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06502015 currently recruiting?
Yes, NCT06502015 is actively recruiting participants. Contact the research team at zhouluoqi@tjh.tjmu.edu.cn for enrollment information.
Where is the NCT06502015 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT06502015 clinical trial?
NCT06502015 is sponsored by Tongji Hospital. The principal investigator is Dai-shi Tian, MD at Tongji Hospital. The trial plans to enroll 50,000 participants.